

RECORDATI: 2018 CORPORATE EVENTS' CALENDAR

Milan, 28 November 2017 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2018:

- | | |
|-------------------|--|
| 8 February | Board of Directors' meeting to approve the 2017 preliminary consolidated results. |
| 15 March | Board of Directors' meeting to approve the 2017 consolidated financial statements and the draft of Recordati S.p.A.'s 2017 financial statements. |
| 18 April | Annual Shareholders' Meeting to approve the 2017 financial statements. |
| 8 May | Board of Directors' meeting to approve the 2018 first quarter results ¹ . |
| 26 July | Board of Directors' meeting to approve the 2018 half-yearly report. |
| 30 October | Board of Directors' meeting to approve the 2018 first nine months' results ² . |

Recordati S.p.A. announces that the payment of the balance of the 2017 financial year dividend is planned for 25 April 2018, on each outstanding share at 23 April 2018 (ex-dividend date) and record date 24 April 2018, while payment of the interim dividend for the 2018 financial year is planned for 21 November 2018, on each outstanding share at 19 November 2018 (ex-dividend date) and record date 20 November 2018.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.

For further information:

Recordati website: www.recordati.com

¹ Please be reminded that, as a result of the fact that Italian Legislative Decree n. 25/2016 enacting Directive 2013/50/EU eliminated the mandatory requirement to disclose the interim financial report, Recordati S.p.A. has decided, pursuant to art.82-ter of Issuers Regulation, to continue disclosing the quarterly reports, on a voluntary basis and until any different decision is taken in this respect, with comparable form and content to those of the previous financial years.

² Please see note n.1 above.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.